© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Research Summaries
Using the drop-down menu below, read about highlighted scientific news from ASCO's Annual Meetings since 2002. You can select a specific year and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
The 2013 ASCO Annual Meeting is set for May 31-June 4, with research news beginning to be released on May 15 at 6pm Eastern. Additional research will be released each day of the meeting.
To read these summaries categorized into a yearly newsletter, you can also review Cancer Advances: News for Patients from the ASCO Annual Meeting.
Don’t forget to check out audio podcasts and videos about this news, as well. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at the ASCO Annual Meeting. To search the entire collection of meeting abstracts, visit ASCO's website.
May 18, 2011
In a recent study, the drug cabozantinib helped manage various advanced cancers, particularly prostate, ovarian, and liver cancers. The drug also helped shrink bone metastases (cancer that has spread to the bone). Cabozantinib is a type of targeted therapy, which means it targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
June 4, 2007
A new study shows that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44% longer than patients who did not receive this drug. Sorafenib is a pill that is taken by mouth. It is approved in the United States for treating a type of advanced kidney cancer and is being studied for treating other cancers.